Amanda Lewis

Amanda M. Lewis is the Senior Director of Quality Operations for Moderna’s Individualized Neoantigen Therapy program.  Amanda joined Moderna in Feb 2023 to support this patient specific medicine focused on oncology indications, and has been accountable for building out a team to support Phase 3 studies and commercial readiness. 

Prior to joining Moderna, Amanda was the Director of BioProcess Technology in Manufacturing Sciences and Technology at Bristol Myers Squibb, and lead a team of scientists and engineers accountable for technical stewardship of commercial biologics processes at the Devens, Massachusetts and Syracuse, New York manufacturing sites.  This includes leveraging state of the art laboratory and scientific expertise in cell culture, purification sciences, and analytical sciences to support commercial biologics programs.  She has held prior roles in Process Development, Manufacturing Sciences & Technology, and Quality Assurance. She has technical expertise in biologics manufacturing, process control, glycosylation, systems biology, and ‘omics technologies.  In 2018, she received the Martin Sinacore Young Investigator Award.  She has co-authored 18 peer-reviewed publications, presented at numerous scientific conferences, and served as a guest editor for Biotechnology & Bioengineering.  She currently serves on the External Advisory Council for the University of Texas at Austin McKetta Chemical Engineering Department.  Amanda received her BS from the Massachusetts Institute of Technology and PhD from The University of Texas at Austin, both in Chemical Engineering.